Bbva Compass Bancshares Inc. reduced its position in shares of Celgene Corporation (NASDAQ:CELG) by 6.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,879 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the quarter. Bbva Compass Bancshares Inc.’s holdings in Celgene Corporation were worth $2,971,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Neuberger Berman Group LLC raised its holdings in Celgene Corporation by 4.0% during the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after purchasing an additional 71,729 shares during the last quarter. Lincoln Capital Corp raised its holdings in Celgene Corporation by 0.6% during the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after purchasing an additional 185 shares during the last quarter. Swiss National Bank raised its holdings in Celgene Corporation by 27.2% during the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock worth $341,796,000 after purchasing an additional 588,000 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Celgene Corporation by 9.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after purchasing an additional 54,210 shares during the last quarter. Finally, Boston Partners raised its holdings in Celgene Corporation by 0.3% during the 1st quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock worth $24,620,000 after purchasing an additional 541 shares during the last quarter. 79.33% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/20/bbva-compass-bancshares-inc-sells-1600-shares-of-celgene-corporation-celg.html.

In related news, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now directly owns 76,301 shares in the company, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 248,976 shares of company stock worth $33,420,421. 0.95% of the stock is owned by insiders.

CELG has been the subject of several recent research reports. Leerink Swann raised Celgene Corporation from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $94.42 to $150.00 in a report on Friday, June 16th. They noted that the move was a valuation call. William Blair restated an “outperform” rating on shares of Celgene Corporation in a research report on Monday, June 26th. Cantor Fitzgerald restated a “buy” rating on shares of Celgene Corporation in a research report on Monday, August 28th. BTIG Research lowered Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Finally, BidaskClub upgraded Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. Celgene Corporation presently has an average rating of “Buy” and an average target price of $149.34.

Shares of Celgene Corporation (NASDAQ:CELG) opened at 143.47 on Wednesday. The stock’s 50 day moving average price is $135.45 and its 200-day moving average price is $127.81. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $144.00. The company has a market cap of $112.24 billion, a PE ratio of 44.43 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. Celgene Corporation’s quarterly revenue was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.44 earnings per share. Analysts expect that Celgene Corporation will post $7.32 EPS for the current year.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.